Our results indicate that several risk factors significantly increase the risk of development of uncomplicated PUD in new users of low-dose ASA.
The crude incidence of uncomplicated PUD in new users of low-dose ASA was 1.41 per 1000 person-years (95% CI, 1.26-1.58).
Among the comorbidities investigated, an increased risk of uncomplicated PUD in new users of low-dose ASA was associated with anaemia (adjusted OR, 2.53; 95% CI, 1.82-3.53), stress (adjusted OR, 1.58; 95% CI, 1.06-2.33) andepressionon (adjusted OR, 1.38; 95% CI, 1.04-1.83).
Our results indicate that the development of uncomplicated PUD in new users of low-dose ASA for the prevention of cardiovascular events was associated with social deprivation, a history of PUD, smoking, stress, depression, anaemia and use of NSAIDs, COX-2 inhibitors and oral steroids.
The incidence of uncomplicated PUD in new users of low-dose ASA who were exposed to a PPI at their start date was also compared with the incidence in those who were not exposed to a PPI at their start date.
An association between acid-suppressing drugs and uncomplicated PUD was observed: current users of PPIs and current users of histamine-2 receptor antagonists (H2RAs) were significantly more likely to have uncomplicated PUD than non-users of these drugs (adjusted OR, 1.68; 95% CI, 1.26-2.25 adjustedsted OR, 2.26; 95% CI, 1.34-3.82, respectively).
"Content and other services make sense as long as the user experience remains uncomplicated," says Harris.
Other factors that significantly increase the risk of uncomplicated PUD in new ASA users include smoking, depression, anaemia, current use of acid-suppressing drugs and NSAIDs.
Current use of acid-suppressing therapy (PPIs or H2RAs) was associated with an increased risk of developing uncomplicated PUD in new ASA users.
Similarly, the increased risk of uncomplicated PUD observed in current users of H2RAs is likely due to confounding by indication, whereby H2RAs are prescribed to treat the symptoms of uncomplicated PUD.
